GO
| HSI1 | 25,197.13 | -114.08 | 163.00B |
| HSCEI1 | 8,376.10 | -74.00 | 46.88B |
| Back Zoom + Zoom - Block Traded | |
|
HUTCHMED Leaps 11%+ on Heavy Vol. on Licensing Deal with GSK for KRAS-EGFR Antibody-drug Conjugate Cancer Therapy
2026-09-03 13:19:33 HUTCHMED (00013.HK) surged in the afternoon session today (3rd) after reaching a licensing agreement with GSK for a KRAS-EGFR antibody-drug conjugate cancer therapy. The stock once peaked at HKD22.3, and last printed at HKD21.36, up 11.6%, with volume surging to 11.6735 million shares, involving HKD250 million. HUTCHMED announced that it had entered into an exclusive development and license agreement with a subsidiary of GSK plc, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-drug conjugate. Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a USD110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of USD1.295 billion, and royalties on net sales. ~ AASTOCKS Financial News Website: www.aastocks.com | |